ombitasvir / paritaprevir / Ritonavir

Known as: OBV/PTV/r, Ombitasvir/Paritaprevir/Ritonavir, ombitasvir, paritaprevir and ritonavir 
An orally bioavailable combination agent containing ombitasvir, an inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A… (More)

Topic mentions per year

Topic mentions per year

2015-2017
05101520152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
  • table 4
Is this relevant?
2017
2017
Limited data are available on direct-acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe… (More)
  • table 1
Is this relevant?
2017
2017
Background Ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV) is approved for hepatitis C virus… (More)
Is this relevant?
2017
2017
INTRODUCTION In Japan, hepatitis C virus (HCV) genotype (GT) 2 accounts for approximately 32% of HCV infections. Limited… (More)
Is this relevant?
2016
2016
BACKGROUND Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV… (More)
Is this relevant?
2016
2016
BACKGROUND & AIMS Orthotopic liver transplant patients with recurrent hepatitis C (HCV) historically have had limited treatment… (More)
Is this relevant?
2016
2016
OBJECTIVES:Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
2016
2016
OBJECTIVE This study compared the cost-effectiveness of chronic hepatitis C virus (HCV) genotype 1b (GT1b) therapy ombitasvir… (More)
Is this relevant?
2015
2015
UNLABELLED GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV… (More)
Is this relevant?